David S. Shames

19.3k citations
110 papers · 6.1k · 1 hit paper · h-index 45

Impact in

  • Cancer Research top 0.5%
    • Cancer Genomics and Diagnostics
  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Cells and Metastasis

Papers in

  • Oncology 78
    • Cancer Immunotherapy and Biomarkers 37
    • Colorectal Cancer Treatments and Studies 14
    • Lung Cancer Research Studies 14
    • Cancer Cells and Metastasis 9
  • Pulmonary and Respiratory Medicine 53
    • Lung Cancer Treatments and Mutations 44
Co-authors
John D. Minna (27 shared papers)Adi F. Gazdar (16 shared papers)Mitsuo Sato (12 shared papers)Tony Mok (15 shared papers)Ignacio I. Wistuba (9 shared papers)Noriaki Sunaga (6 shared papers)Luc Girard (12 shared papers)Kenneth E. Huffman (2 shared papers)
Journals
Cancer Research (16 papers)Journal of Clinical Oncology (13 papers)Annals of Oncology (10 papers)Journal of Thoracic Oncology (9 papers)Clinical Cancer Research (7 papers)
Partner nations
United StatesChinaSwitzerland

In The Last Decade

David S. Shames

106 papers receiving 6.0k citations

David S. Shames's Hit Papers

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy 2015 · 367 citations
3670+3+7Years since publication100200300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2015 Clinical Cancer Research

Peers

David S. Shames
Comparison fields: 5 of 119
  • Cancer Research 1.9k
  • Oncology 2.9k
  • Pulmonary and Respiratory Medicine 2.4k
  • Molecular Biology 3.0k
  • Hepatology 310
Replace Laura D. Wood with:
Laura D. Wood United States
Daniele Generali Italy
Jianping Xiong China
E. Gabriela Chiorean United States
Ryan B. Corcoran United States
Katsuya Tsuchihara Japan
Marcella Mottolese Italy
Brigitte Bressac–de Paillerets France
Viviana Bazan Italy
Niels Reinmuth Germany
David S. Shames relative to Laura D. Wood United States Laura D. Wood's profile →
Citations per field
00.5×1.5×
Laura D. Wood · 1×
Citations per year

Countries citing papers authored by David S. Shames

Since Specialization
Citations

This map shows the geographic impact of David S. Shames's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Shames with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Shames more than expected).

Fields of papers citing papers by David S. Shames

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Shames. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Shames. The network helps show where David S. Shames may publish in the future.

Co-authors

The 25 scholars most cited alongside David S. Shames, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David S. Shames Line = papers co-authored together David S. Shames links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Clinical Cancer Research ·Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu
Hit paper breakdown →		2015367
2
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing
Nature Structural & Molecular Biology ·Bethany A. Janowski, Kenneth E. Huffman, Jacob C. Schwartz, Rosalyn Ram, Robert Nordsell, David S. Shames, John D. Minna, David R. Corey
2006264
3
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
Journal of Clinical Oncology ·David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok
2017232
4
A Translational View of the Molecular Pathogenesis of Lung Cancer
Journal of Thoracic Oncology ·Mitsuo Sato, David S. Shames, Adi F. Gazdar, John D. Minna
2007212
5
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
JAMA Oncology ·Manish A. Shah, Yung‐Jue Bang, Florian Lordick, María Alsina, Meng Chen, Stephen P. Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S. Shames, See Phan, David Cunningham
2016209
6
Multiple Oncogenic Changes (K-RASV12, p53 Knockdown,Mutant EGFRs, p16Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells
Cancer Research ·Mitsuo Sato, Melville B. Vaughan, Luc Girard, Michael Peyton, Woochang Lee, David S. Shames, Ruben D. Ramirez, Noriaki Sunaga, Adi F. Gazdar, Jerry W. Shay, John D. Minna
2006207
7
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
PLoS ONE ·Junichi Soh, Naoki Okumura, William W. Lockwood, Hiromasa Yamamoto, Hisayuki Shigematsu, Wei Zhang, Raj Chari, David S. Shames, Ximing Tang, Calum MacAulay, Marileila Varella‐Garcia, Tõnu Vooder, Ignacio I. Wistuba, Stephen Lam, Rolf A. Brekken, Shinichi Toyooka, John D. Minna, Wan L. Lam, Adi F. Gazdar
2009179
8
Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice
Cancer Research ·Seán Dineen, Kristi D. Lynn, Shane E. Holloway, Andrew F. Miller, James P. Sullivan, David S. Shames, Adam W. Beck, Carlton C. Barnett, Jason B. Fleming, Rolf A. Brekken
2008161
9
DNA Methylation in Health, Disease, and Cancer
Current Molecular Medicine ·David S. Shames, John D. Minna, Adi F. Gazdar
2007159
10
Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
Molecular Cancer Research ·Mitsuo Sato, Jill E. Larsen, Woochang Lee, Han Sun, David S. Shames, Maithili P. Dalvi, Ruben D. Ramirez, Hao Tang, J. Michael DiMaio, Boning Gao, Yang Xie, Ignacio I. Wistuba, Adi F. Gazdar, Jerry W. Shay, John D. Minna
2013156
11
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
Cell Reports ·Leonard D. Goldstein, James Lee, Florian Gnad, Christiaan Klijn, Annalisa Schaub, Jens Reeder, Anneleen Daemen, Corey E. Bakalarski, Thomas Holcomb, David S. Shames, Ryan J. Hartmaier, Juliann Chmielecki, Somasekar Seshagiri, Robert Gentleman, David Stokoe
2016151
12
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner
2012149
13
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
Cancer Research ·Triparna Sen, Pan Tong, C. Allison Stewart, Sandra Cristea, Aly Valliani, David S. Shames, Abena B. Redwood, You Hong Fan, Lerong Li, Bonnie S. Glisson, John D. Minna, Julien Sage, Don L. Gibbons, Helen Piwnica‐Worms, John V. Heymach, Jing Wang, Lauren A. Byers
2017145
14
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Molecular Cancer Therapeutics ·Christina L. Roland, Seán Dineen, Kristi D. Lynn, Laura A. Sullivan, Michael T. Dellinger, Leila Sadegh, James P. Sullivan, David S. Shames, Rolf A. Brekken
2009144
15
Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs
Nature Chemical Biology ·Bethany A. Janowski, Kenneth E. Huffman, Jacob C. Schwartz, Rosalyn Ram, Daniel B. Hardy, David S. Shames, John D. Minna, David R. Corey
2005141
16
RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells
Cancer Research ·Makoto Suzuki, Noriaki Sunaga, David S. Shames, Shinichi Toyooka, Adi F. Gazdar, John D. Minna
2004140
17
Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Molecular Cancer Therapeutics ·Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori, John D. Minna
2011135
18
Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
Cancer Cell ·Timothy R. Wilson, Diana Lee, Leanne Berry, David S. Shames, Jeff Settleman
2011125
19
Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.
Journal of Clinical Oncology ·David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, David S. Shames, Wei Yu, Virginia Paton, Tony Mok
2014115
20
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
Nature Medicine ·Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski
2022111

About David S. Shames

David S. Shames is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 110 papers that have together received 6.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (37 papers), Cancer Genomics and Diagnostics (36 papers), Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Research Studies (14 papers), RNA modifications and cancer (12 papers), Epigenetics and DNA Methylation (12 papers) and Cancer Cells and Metastasis (9 papers). The work is most often cited by research in Cancer Research (1.9k citations), Oncology (2.9k citations), Pulmonary and Respiratory Medicine (2.4k citations), Molecular Biology (3.0k citations) and Hepatology (310 citations). David S. Shames has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include John D. Minna, Adi F. Gazdar, Mitsuo Sato, Tony Mok, Ignacio I. Wistuba, Noriaki Sunaga, Luc Girard, Kenneth E. Huffman, Bethany A. Janowski and Rosalyn Ram. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura D. WoodBreakdown of academic impact, for papers by Daniele GeneraliBreakdown of academic impact, for papers by Jianping XiongBreakdown of academic impact, for papers by E. Gabriela ChioreanBreakdown of academic impact, for papers by Ryan B. CorcoranBreakdown of academic impact, for papers by Katsuya TsuchiharaBreakdown of academic impact, for papers by Marcella MottoleseBreakdown of academic impact, for papers by Brigitte Bressac–de PailleretsBreakdown of academic impact, for papers by Viviana BazanBreakdown of academic impact, for papers by Niels Reinmuth